Delivery Order SPE2DB22D1002-SPE2DB24FLHZ7

Award Date 9/18/24
Potential Completion Date 9/19/24
Potential Value $6.5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corporation, a subsidiary of Amerisourcebergen Corporation, a firm fixed price delivery order contract valued at $6,296.68 for the supply of REXULTI 0.5 MG TABLET 30S. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract...
The U.S. Defense Logistics Agency (DLA) awarded a $12,307.88 firm fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of REXULTI 2 MG TABLET 30S. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally....
This $36,630.61 firm fixed-price delivery order was awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The award covers the delivery of the pharmaceutical product REXULTI 1 MG TABLET 30S, with a performance period through January 21, 2025. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $32,326.93 firm-fixed-price delivery order is for REXULTI 2 MG tablets. The contract has an ultimate completion date of March 6, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
The U.S. Department of Defense's Defense Logistics Agency (DLA) Troop Support Medical has awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, a leading global pharmaceutical sourcing and distribution company. The contract, valued at $13,652.36, is for the delivery of REXULTI 4 MG TABLET 30S, a pharmaceutical product, with a period of performance through April 15, 2024. This delivery order is part of a larger indefinite...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide the pharmaceutical product REXULTI 0.5 MG TABLET 30S. The order has a completion date of March 8, 2024 and a potential value of $4,592.77. Amerisourcebergen Drug Corp is a prime contractor that holds an indefinite delivery contract (IDC) with DLA, valued up to $999,999,999.00 through December 31, 2025, to deliver a...
This is a $2,820.09 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of the antipsychotic medication REXULTI 1 MG TABLET 30S. The order has a performance period ending on June 24, 2025. Amerisourcebergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which provides a comprehensive global pharmaceutical support vehicle through...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, involves the delivery of REXULTI 2 MG TABLET 30S to the Defense Logistics Agency (DLA). The $8,479.18 firm fixed-price delivery order has a completion date of May 19, 2025 and is not set aside. Amerisourcebergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products and medical supplies to...
This is a $6,945.70 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of REXULTI 2 MG TABLET 30S, a pharmaceutical product, with a period of performance through April 4, 2025. The contract was not set aside for any specific business type. AmerisourceBergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $17,551.82 Firm Fixed Price Delivery Order is for the supply of REXULTI 1 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of February 7, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
  • SPE2DB22D1002
    Indefinite Delivery Contract
  • SPE2DB22D1002-SPE2DB24FLHZ7
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a $6,495.49 firm-fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of 1 mg REXULTI tablets. This order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 that AmerisourceBergen holds with DLA Troop Support Medical to provide a comprehensive range of pharmaceutical and medical supplies in support of military healthcare programs. The contract does not have a set-aside designation and is expected to be completed by September 19, 2024. AmerisourceBergen, a major pharmaceutical distributor, leverages its extensive supply chain to deliver critical medications and medical commodities to federal agencies and healthcare facilities nationwide.

Generated 12/18/24, 9:02 AM